$ZNTL: Oncology MomentumZNTL broke 80 again today and is displaying a strong monthly momentum chart. IBB regaining 160 hopefully will signal at least a moderate health care push that could push ZNTL into the 90s and beyond. Good luck traders!
−4.56USD
−292.19 MUSD
63.80 M
About Zentalis Pharmaceuticals, Inc.
Sector
Industry
CEO
Kimberly L. Blackwell
Website
Headquarters
New York
Employees (FY)
168
Founded
2014
ISIN
US98943L1070
FIGI
BBG00R2K8TF5
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.
ZNTL Oversold.... bounce time? Looking for oversold confirmation and bounce
Oversold on all the scanners looking for a bounce back up to $42+
Potential double bottom...
Still lots of insider selling in the $50-$37 range.
Looking for a shake out and bounce.
Average Target Price 58.33
Both its technical analysis and fundamental reports look great. Both its technical analysis and fundamental reports look great. This is a perfect time to buy this stock.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ZNTL is 12.68 USD — it has increased by 1.12% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Zentalis Pharmaceuticals, Inc. stocks are traded under the ticker ZNTL.
Zentalis Pharmaceuticals, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
ZNTL stock is 6.26% volatile and has beta coefficient of 1.27. Check out the list of the most volatile stocks — is Zentalis Pharmaceuticals, Inc. there?
One year price forecast for Zentalis Pharmaceuticals, Inc. has a max estimate of 50.00 USD and a min estimate of 15.00 USD.
ZNTL earnings for the last quarter are −0.79 USD per share, whereas the estimation was −0.93 USD resulting in a 15.31% surprise. The estimated earnings for the next quarter are −0.82 USD per share. See more details about Zentalis Pharmaceuticals, Inc. earnings.
Yes, you can track Zentalis Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
ZNTL stock has fallen by 4.01% compared to the previous week, the month change is a 10.33% fall, over the last year Zentalis Pharmaceuticals, Inc. has showed a 35.96% decrease.
ZNTL net income for the last quarter is −60.92 M USD, while the quarter before that showed −55.53 M USD of net income which accounts for −9.71% change. Track more Zentalis Pharmaceuticals, Inc. financial stats to get the full picture.
Today Zentalis Pharmaceuticals, Inc. has the market capitalization of 889.84 M, it has increased by 1.32% over the last week.
No, ZNTL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ZNTL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Zentalis Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 168.00 employees. See our rating of the largest employees — is Zentalis Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Zentalis Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Zentalis Pharmaceuticals, Inc. stock shows the sell signal. See more of Zentalis Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Zentalis Pharmaceuticals, Inc. future price: according to them, ZNTL price has a max estimate of 50.00 USD and a min estimate of 15.00 USD. Read a more detailed Zentalis Pharmaceuticals, Inc. forecast: see what analysts think of Zentalis Pharmaceuticals, Inc. and suggest that you do with its stocks.